Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research


1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 2University of Minnesota Medical Center, Minneapolis, MN, USA; 3CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA; 4Division of Biostatistics, Institute for Health and Education, Medical College of Wisconsin, Milwaukee, WI, USA; 5Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA; 6Adult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, UK; 7Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA; 8Levine Cancer Institute, Atrium Health, Carolinas HealthCare System, Charlotte, NC, USA; 9Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; 10Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA; 11Division of Cell Therapy and Hematology, Department of Medicine, Duke University Medical Center, Durham, NC, USA; 12Blood and Cancer Centre, Starship Children's Hospital, Auckland, New Zealand; 13Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 14Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, TX, USA; 15Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan; 16Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; 17Department of Internal Medicine, Mayo Clinic, MN, USA; 18Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; 19Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA; 20Department of Hematology, Inselspital, Bern University Hospital, Switzerland; 21Markey Cancer Center, University of Kentucky, Lexington, KY, USA; 22Loyola University Medical Center, Maywood, IL, USA; 23University of Kansas Medical Center, Westwood, KS, USA; 24City of Hope Comprehensive Cancer Center, Duarte, CA, USA; 25University of Miami, Miami, FL, USA; 26Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA, USA; 27Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO, USA; 28Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; 29Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden; 30Vanderbilt University Medical Center, Nashville, TN, USA; 31Department of Pediatric Hematology, Oncology and Bone Marrow Transplant, British Columbia's Children's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada; 32Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, Manitoba, Canada; 33Tom Baker Cancer Centre, Calgary, Alberta, Canada; 34Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; 35Department of Hematology/Oncology, Isala Clinic, Zwolle, the Netherlands; 36Division of Hematology and Oncology, Department of Stem Cell Transplantation, Department of Pediatrics, New York Medical College, Valhalla, NY, USA; 37Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA; 38The Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA; 39The Children's Hospital at TriStar Centennial and Sarah Cannon Research Institute, Nashville, TN, USA; 40Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA; 41Section of Hematology/Oncology, Department of Internal Medicine, Louisiana State University Health Science Center, Shreveport, LA, USA; 42Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA; 43Department of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA; 44Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA; 45Translational Therapy Group, CLINTEC (Clinical Science, Intervention and Technology), Karolinska Institutet, Stockholm, Sweden; 46Academische Ziekenhuis Maastricht, Maastricht, the Netherlands; 47Mayo Clinic Florida, Jacksonville, FL, USA; 48University of Chicago Medicine, Chicago, IL, USA; 49Blood & Marrow Transplant Center, Florida Hospital Medical Group, Orlando, FL, USA; 50UCAL Medical Center, Los Angeles, CA, USA; 51The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA; 52OllQ Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada; 53Hospital Vall d’Hebron, Barcelona, Spain; 54Rush University Medical Center, Chicago, IL, USA; 55Christian Medical College, Vellore, India; 56Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI, USA; 57Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA; 58Division of Hematology-Oncology, Indiana University School of Medicine, Indianapolis, IN, USA; 59National Cancer Institute (NCI), Rockville, MD, USA; 60New York Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA; 61UH Health Shands Children's Hospital, Gainesville, FL, USA; 62Department of Advanced Medicine, NagoYa University Hospital, NagoYa, Japan; 63Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan; 64Division of Hematology/Oncology/Cell Therapy, Rush University, Chicago, IL, USA; 65Memorial Sloan Kettering Cancer Center, New York, NY, USA; 66Case Western Reserve University, Cleveland, OH, USA; 67Division of Medical Oncology, University of Washington and Clinical Research Division, Fred Hutchinson
Supplemental Figure. Adjusted Relapse by CIBMTR ALL risk scheme

- Favorable (n=28)
- Intermediate (n=1566)
- Adverse (n=125)

\( p < 0.001 \)